REGEN BIOPHARMA, INC. Stock Issued During Period, Value, New Issues
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- REGEN BIOPHARMA, INC. stock issued during period, value, new issues for the quarter ending 2026-06-30 was $0.00, a 100.00% decline year-over-year.
- REGEN BIOPHARMA, INC. stock issued during period, value, new issues for the quarter ending 2026-03-31 was $50.00K.
- REGEN BIOPHARMA, INC. stock issued during period, value, new issues for the quarter ending 2025-12-31 was $191.80K.
- REGEN BIOPHARMA, INC. stock issued during period, value, new issues for the quarter ending 2025-09-30 was $58.20K, a 106.93% increase year-over-year.
- REGEN BIOPHARMA, INC. stock issued during period, value, new issues for fiscal 2025 was $141.91K, a 74.83% decline from fiscal 2024.
- REGEN BIOPHARMA, INC. stock issued during period, value, new issues for fiscal 2024 was $563.72K.
| Period end | Stock Issued During Period, Value, New Issues 3 month | Stock Issued During Period, Value, New Issues 12 month |
|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2026-08-17 | $300.00K derived: sum of 4 quarters · filed 2026-08-17 |
| 2026-03-31 | $50.00K 10-Q · filed 2026-05-14 | $350.00K derived: sum of 4 quarters · filed 2026-08-17 |
| 2025-12-31 | $191.80K 10-Q · filed 2026-02-13 | |
| 2025-09-30 | $58.20K derived: 10-K 12 month − 10-Q 9 month · filed 2025-12-30 | $141.91K 10-K · filed 2025-12-30 |
| 2025-06-30 | $50.00K 10-Q · filed 2026-08-17 | |
| 2024-09-30 | $28.13K 8-K · filed 2024-11-29 | $563.72K 10-K · filed 2025-12-30 |
| 2024-06-30 | $135.33K 10-Q · filed 2025-08-11 | |
| 2024-03-31 | $39.64K 8-K · filed 2024-11-29 | |
| 2023-12-31 | $212.30K 10-Q · filed 2025-05-16 | |
| 2019-06-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-10-24 | |
| 2018-06-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-10-24 |